Expertise in
10
conditions

Kazutoshi Harada

Tokyo, JP 
Expertise in
10
conditions
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Kazutoshi Harada practices in Tokyo, Japan. Harada is highly rated in 10 conditions, according to our data. Their top areas of expertise are Autosomal Recessive Hypotrichosis, Ringworm, Alopecia Areata, and Oral Squamous Cell Carcinoma.

Their clinical research consists of co-authoring 142 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Tokyo, Japan
Other Locations
Shinjuku, Japan
Shibuya, Japan
Saitama, Japan
Tokorozawa, 3590023, Japan
Chuo, 4093898, Japan
Yamanashi, Japan
Aomori, Japan
Yokohama, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

142 Total Publications

Marked response to dupilumab in an elderly patient with eosinophilic annular erythema.
Marked response to dupilumab in an elderly patient with eosinophilic annular erythema.
Journal: JAAD case reports
Published: October 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Harada's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 42 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile